<DOC>
	<DOCNO>NCT02582242</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare efficacy safety thrice daily versus twice daily NovoMix® 30 ( Biphasic insulin aspart 30 ) subject type 2 diabetes inadequately control basal insulin .</brief_summary>
	<brief_title>Comparing Efficacy Safety Thrice Daily Versus Twice Daily NovoMix® 30 ( Biphasic Insulin Aspart 30 ) Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Male female , age least 18 year time signing informed consent . For Algeria : age least 19 year time signing informed consent Type 2 diabetes subject clinically diagnose least 12 month prior day screen ( Visit 1 ) Treated basal insulin least 90 day prior day screen ( Visit 1 ) . The following basal insulin allow : insulin analogue daily ( OD ) Neutral Protamine Hagedorn ( NPH ) OD BID ( twice daily ) Treatment metformin without one additional OAD ( oral antidiabetic drug ) least 90 day prior day screen ( Visit 1 ) Metformin must stable dose least 1500 mg daily maximum tolerate dose least 60 day prior screen ( Visit 1 ) One additional OAD : Sulphonylurea/Glinides/ aglucosidase inhibitors/Dipeptidylpeptidase4 inhibitors/Sodium glucose cotransporter 2 ( SGLT2 ) inhibitor ( applicable ) HbA1c ( glycosylated haemoglobin ) 7.5 % 10.0 % ( inclusive ) central laboratory analysis screening ( Visit 1 ) Able willing intake three main meal daily ( breakfast , lunch main evening meal ) throughout trial . Definition main meal judge investigator Previous insulin intensification regimen 14 day : premixed insulin thrice daily , basalbolus regimen continuous subcutaneous insulin infusion ( CSII ) . Treatment hospitalisation gestational diabetes allow period longer 14 day Anticipated initiation change concomitant medication 14 consecutive day frequent basis know affect weight glucose metabolism ( e.g . orlistat , thyroid hormone , systemic corticosteroid ) Impaired liver function , define alanine aminotransferase ( ALT ) equal 2.5 time upper normal limit screening ( Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>